Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Table 2

Results of network meta-analysis (data under the cells marked with underlined data) and direct comparison (data above the cells marked with underlined data) of all treatments.

EX10BID

−0.61 kg; (−1.37, 0.15)

−0.66 kg; (−1.11, −0.21)

−4.77 kg; (−5.48, −4.05)

—

—

—

0.37 kg; (−0.55, 1.29)

−1.99 kg; (−2.77, −1.21)

−7.30 kg; (−12.82, −1.78)

−1.00 kg; (−2.14, 0.14)

−4.30 kg; (−5.82, −2.78)

−1.38 kg; (−1.74, −1.03)

−1.00 kg; (−2.01, 0.03)

EX2QW

—

−3.17 kg; (−5.48, −0.85)

—

—

—

0.89 kg; (0.39, 1.39)

0.00 kg; (−1.25, 1.25)

—

−1.38 kg; (−2.06, −0.70)

−4.33 kg; (−5.90, −2.77)

−1.27 kg; (−5.72, 3.18)

−1.07 kg; (−2.14, −0.02)

−0.07 kg; (−1.47, 1.32)

EX5BID

—

—

—

—

—

—

—

—

—

−0.50 kg; (−1.09, 0.09)

−4.52 kg; (−5.39, −3.65)

−3.53 kg; (−4.62, −2.44)

−3.46 kg; (−4.78, −2.11)

Insulin

—

—

—

3.40 kg; (2.49, 4.31)

—

—

—

—

2.02 kg; (1.02, 3.02)

−2.38 kg; (−3.71, −1.06)

−1.38 kg; (−2.91, 0.13)

−1.31 kg; (−2.91, 0.29)

2.14 kg; (0.63, 3.65)

LIR0.6QD

0.70 kg; (−3.19, 4.59)

0.54 kg; (0.23, 0.85)

0.74 kg; (0.42, 1.05)

—

−2.27 kg; (−3.11, −1.42)

—

−1.40 kg; (−1.95, −0.85)

0.33 kg; (−0.22, 0.89)

−2.48 kg; (−5.65, 0.53)

−1.48 kg; (−4.74, 1.67)

−1.40 kg; (−4.70, 1.77)

2.04 kg; (−1.19, 5.16)

−0.10 kg; (−3.24, 2.95)

LIR0.9QD

—

—

—

−2.11 kg; (−6.01, 1.79)

—

—

0.49 kg; (−3.63, 4.60)

−1.62 kg; (−2.79, −0.43)

−0.61 kg; (−2.01, 0.75)

−0.55 kg; (−2.03, 0.93)

2.91 kg; (1.51, 4.29)

0.76 kg; (−0.60, 2.12)

0.87 kg; (−2.24, 4.11)

LIR1.2QD

0.46 kg; (0.11, 0.81)

—

−2.94 kg; (−3.74, −2.14)

−1.62 kg; (−2.48, −0.76)

−1.80 kg; (−2.35, −1.25)

−0.79 kg; (−2.06, 0.48)

−0.95 kg; (−1.93, 0.03)

0.06 kg; (−1.14, 1.26)

0.12 kg; (−1.24, 1.47)

3.58 kg; (2.39, 4.78)

1.43 kg; (0.15, 2.73)

1.53 kg; (−1.50, 4.73)

0.68 kg; (−0.40, 1.74)

LIR1.8QD

—

−3.12 kg; (−3.80, −2.44)

−2.52 kg; (−3.38, −1.66)

−2.30 kg; (−2.85, −1.75)

−1.32 kg; (−2.22, −0.43)

−1.44 kg; (−3.32, 0.45)

−0.43 kg; (−2.41, 1.53)

−0.37 kg; (−2.52, 1.74)

3.10 kg; (1.06, 5.11)

0.95 kg; (−1.32, 3.18)

1.06 kg; (−2.50, 4.66)

0.17 kg; (−1.97, 2.33)

−0.49 kg; (−2.55, 1.51)

Met

—

−1.20 kg; (−2.26, −0.14)

−3.50 kg; (−4.56, −2.44)

—

−5.30 kg; (−6.38, −4.24)

−4.29 kg; (−5.66, −2.91)

−4.23 kg; (−5.65, −2.79)

−0.77 kg; (−2.12, 0.55)

−2.92 kg; (−4.27, −1.53)

−2.82 kg; (−5.85, 0.29)

−3.68 kg; (−4.92, −2.48)

−4.35 kg; (−5.45, −3.24)

−3.87 kg; (−5.99, −1.73)

SU

—

—

2.03 kg; (0.91, 3.15)

−2.21 kg; (−3.59, −0.83)

−1.20 kg; (−2.64, 0.23)

−1.14 kg; (−2.83, 0.55)

2.31 kg; (0.76, 3.85)

0.16 kg; (−1.55, 1.93)

0.27 kg; (−3.01, 3.61)

−0.59 kg; (−2.17, 0.97)

−1.26 kg; (−2.72, 0.19)

−0.77 kg; (−2.87, 1.32)

3.09 kg; (1.49, 4.69)

Sitagliptin

−2.94 kg; (−4.21, −1.67)

−0.30 kg; (−1.37, 0.77)

−4.59 kg; (−5.99, −3.24)

−3.59 kg; (−5.04, −2.16)

−3.53 kg; (−5.23, −1.85)

−0.07 kg; (−1.62, 1.47)

−2.21 kg; (−3.92, −0.53)

−2.11 kg; (−5.31, 1.23)

−2.98 kg; (−4.56, −1.41)

−3.65 kg; (−5.13, −2.19)

−3.16 kg; (−5.26, −1.09)

0.70 kg; (−0.92, 2.27)

−2.38 kg; (−3.95, −0.80)

TZD

2.20 kg; (1.54, 2.86)

−1.92 kg; (−2.61, −1.24)

−0.92 kg; (−2.01, 0.13)

−0.86 kg; (−1.90, 0.20)

2.60 kg; (1.56, 3.62)

0.46 kg; (−0.80, 1.71)

0.56 kg; (−2.48, 3.68)

−0.31 kg; (−1.44, 0.81)

−0.98 kg; (−1.94, −0.02)

−0.49 kg; (−2.45, 1.46)

3.37 kg; (2.29, 4.48)

0.28 kg; (−1.09, 1.67)

2.67 kg; (1.28, 4.07)

Placebo

Treatments are reported in alphabetical order. For data above the cells marked with underlined data, comparisons between treatments should be read from left to right and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment; for data under the cells marked with underlined data, it is reverse order to read the results. EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR0.9: liraglutide 0.9 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily; SU: sulfonylureas; TZD: thiazolidinediones; Met: metformin.